Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies

European Journal of Haematology

Volumn 74, Issue 2, 2005, Pages 144-151

  Valcarcel D ^a   Martino, Rodrigo ^a,b   Sureda, A ^a   Canals, C ^a   Altes A ^a   Briones, J ^a   Sanz, M A ^a   Parody, R ^a   Constans, M ^a   Villela, S L ^a   Brunet, S ^a   Sierra, J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Reduced intensity conditioning regimens; Therapy related mortality

Indexed keywords

BUSULFAN; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; INTERLEUKIN 2; LYMPHOCYTE ANTIBODY; METHOTREXATE; PREDNISONE; THIOTEPA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA SYSTEM; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SIBLING; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE DEPLETION; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 19944433633     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00360.x     Document Type: Article

References (24)

1. CARELLA AM, GIRALT S, SLAVIN S. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica 2000;85:304-313.
2. CHILDS R, CLAVE E, CONTENTIN N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor t-cell chimerism precedes alloimmune responses. Blood 1999;94:3234-3241.
3. GIRALT S, ESTEY E, ALBITAR M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
4. GIRALT S, THALL PF, KHOURI I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-637.
5. KHOURI IF, KEATING M, KORBLING M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.
6. KOTTARIDIS PD, MILLIGAN DW. CHOPRA R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000;96:2419-2425.
7. MARTINO R, CABALLERO MD, CANALS C, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 2001;115:653-659.
8. MCSWEENEY PA, NIEDERWIESER D, SHIZURU JA, et al. Hematopoietic stem cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-host-tumor effects. Blood 2001;97:3390-3400.
9. SLAVIN S, NAGLER A, NAPARSTEK E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-763.
10. DIACONESCU R, FLOWERS CR, STORER B, SORROR ML, MARIS MB, MALONEY DG, SANDMAIER BM, STORB R. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood 2004;104:1550-1558.
11. SORROR ML, MARIS MB, STORER B, SANDMAIER BM, DIACONESCU R, FLOWERS C, MALONEY DG, STORB R. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood 2004;104:961-968.
12. COURIEL DR, SALIBA RM, GIRALT S, et al. Acute and chronic graft-versus-host disease after ablative and non-myeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10:178-185.
13. FERRARA JLM, DEEG HJ. Graft versus host disease. N Engl J Med 1991;324:667-674.
14. PRZEPIORKA D, WEISDORF D, MARTIN P, KLINGEMANN HG, BEATTY P, HOWS J, THOMAS ED. Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-830.
15. CANALS C, MARTINO R, SUREDA A, ALTES A, BRIONES J, SUBIRA M, ANCIN I, MARTIN-HENAO G, BRUNET S, SIERRA J. Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. Exp Hematol 2003;31:1039-1043.
16. MIELCAREK M, MARTIN PJ, LEISENRING W, FLOWERS ME, MALONEY DG, SANDMAIER BM, MARIS MB, STORB R. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-762.
17. FERRARA JL, LEVY R, CHAO NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 1999;5:347-356.
18. PEREZ-SIMON JA, DIEZ-CAMPELO M, MARTINO R, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003; 102:1108-1113.
19. HO VT, SOIFFER RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001;98:3192-3204.
20. LEVINE JE, UBERTI JP, AYASH L, REYNOLDS C, FERRARA JL, SILVER SM, BRAUN T, YANIK G, HUTCHINSON R, RATANATHARATHORN V. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant 2003;9:189-197.
21. MINEISHI S, KANDA Y, SAITO T, NAKAI K, MAKIMOTO A, KAMI M, TANOSAKI R, WAKASUGI H, TOBINAI K, TAKAUE Y. Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (rist) for patients with hematological malignancies. Br J Haematol 2003;121:296-303.
22. MATTSSON J, UZUNEL M, BRUNE M, HENTSCHKE P, BARKHOLT L, STIERNER U, ASCHAN J, RINGDEN O. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2001;115:935-944.
23. NAGLER A, ACKERSTEIN A, KAPELUSHNIK J, OR R, NAPARSTEK E, SLAVIN S. Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplant 1999;24:339-342.
24. VALCARCEL D, MARTINO R, CABALLERO D, et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2003;31:387-392.